Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin

[1]  A. Oza,et al.  A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. , 2015, Gynecologic oncology.

[2]  Andrew L. Kung,et al.  Examining the utility of patient-derived xenograft mouse models , 2015, Nature Reviews Cancer.

[3]  P. Ostano,et al.  Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. , 2014, Cancer research.

[4]  P. Carmeliet,et al.  Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease , 2014, EMBO molecular medicine.

[5]  B. Monk,et al.  Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.

[6]  G. Hortobagyi,et al.  Past, present, and future challenges in breast cancer treatment. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Kohn,et al.  Better therapeutic trials in ovarian cancer. , 2014, Journal of the National Cancer Institute.

[8]  G. Taraboletti,et al.  Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. , 2014, The American journal of pathology.

[9]  M. Pichler,et al.  Tumor Macroenvironment and Metabolism , 2014, Seminars in oncology.

[10]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Janku.  Tumor heterogeneity in the clinic: is it a real problem? , 2014, Therapeutic advances in medical oncology.

[12]  R. Eskander,et al.  Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications. , 2014, Gynecologic oncology.

[13]  C. Punt,et al.  A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion , 2014, Targeted Oncology.

[14]  G. Jayson,et al.  Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial , 2013 .

[15]  Peter J. Selby,et al.  Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection , 2013, Clinical Cancer Research.

[16]  E. Scanziani,et al.  Chemotherapy Counteracts Metastatic Dissemination Induced by Antiangiogenic Treatment in Mice , 2013, Molecular Cancer Therapeutics.

[17]  B. Monk,et al.  Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J Ledermann,et al.  Targeted anti-vascular therapies for ovarian cancer: current evidence , 2013, British Journal of Cancer.

[19]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[20]  E. Scanziani,et al.  Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models , 2012, British Journal of Cancer.

[21]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[22]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[23]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[24]  D. Morris,et al.  Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer , 2011, Cancer and Metastasis Reviews.

[25]  J. Ledermann,et al.  Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer , 2011, British Journal of Cancer.

[26]  A. Awada,et al.  Is VEGF a predictive biomarker to anti-angiogenic therapy? , 2011, Critical reviews in oncology/hematology.

[27]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Christian Marth,et al.  2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference , 2011, International Journal of Gynecologic Cancer.

[29]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[30]  Percy Ivy,et al.  Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[32]  R. Jain,et al.  Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib , 2008, Molecular Cancer Therapeutics.

[33]  K. Alitalo,et al.  The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. , 2008, Cancer research.

[34]  G. Taraboletti,et al.  Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion , 2008, Molecular Cancer Research.

[35]  G. Jayson,et al.  Antiangiogenic therapy for ovarian cancer , 2007, Current opinion in oncology.

[36]  S. Barry,et al.  Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts , 2007, Molecular Cancer Therapeutics.

[37]  A. Jubb,et al.  Predicting benefit from anti-angiogenic agents in malignancy , 2006, Nature Reviews Cancer.

[38]  S. Barry,et al.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.

[39]  R. Labianca,et al.  Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. , 2003, European journal of cancer.

[40]  J. Cherrington,et al.  The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[42]  E. Smit,et al.  Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. , 2000, The oncologist.

[43]  N. Ferrara,et al.  Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. , 1998, The American journal of pathology.

[44]  E. Manseau,et al.  Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. , 1995, Cancer research.

[45]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[46]  P. Allavena,et al.  Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy , 1989, International journal of cancer.

[47]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[48]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .

[49]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.